产品名称
C24:0 Ceramide (d18:2(4E,8Z)/24:0), Avanti Research™ - A Croda Brand 860693P, powder
InChI
1S/C42H81NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h27,29,35,37,40-41,44-45H,3-26,28,30-34,36,38-39H2,1-2H3,(H,43,46)/b29-27-,37-35+/t40-,41+/m0/s1
InChI key
ZCUCZYYSYGKQQV-PZYFEVQHSA-N
SMILES string
OC[C@@](NC(CCCCCCCCCCCCCCCCCCCCCCC)=O)([H])[C@]([H])(O)/C=C/CC/C=C\CCCCCCCCC
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 mg (860693P-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 860693P
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
General description
C24:0 Ceramide (d18:2(4E,8Z)/24:0), also known as N-lignoceroyl-D-erythro-sphingosine (d18:2(4E,8Z) base), is a very long chain plasma ceramide derived from sphingosine containing two double bonds with lignoceric acid.
Biochem/physiol Actions
Altered levels of C24:0 Ceramide has been observed in mild cognitive impairment (MCI) patients. It acts as a primary biomarker of Alzheimer disease (AD) progression.
Packaging
5 mL Amber Glass Screw Cap Vial (860693P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
No data available
flash_point_c
No data available
Michelle M Mielke et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 6(5), 378-385 (2010-09-04)
A blood-based biomarker of Alzheimer's disease (AD) would be superior to cerebrospinal fluid (CSF) and neuroimaging measures in terms of cost, invasiveness, and feasibility for repeated measures. We previously reported that blood ceramides varied in relation to timing of memory
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持